CBIO

Crescent Biopharma, Inc. (CBIO) - Q2 2026 10-Q Summary

Business Context and Reporting Period

Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing oncology therapeutics, specifically bispecific antibodies and antibody-drug conjugates (ADCs). The company operates as a smaller reporting company and is incorporated in the Cayman Islands. This report covers the quarterly period ended June 30, 2026.

The company's pipeline centers on three primary programs: CR-001 (a PD-1 x VEGF bispecific antibody), CR-002 (a PD-L1-directed ADC), and CR-003 (formerly SKB105, an integrin beta-6-directed ADC). The company has no products approved for commercial sale and has historically incurred significant losses.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $1.0 million in revenue for the six months ended June 30, 2026, derived from the transfer of initial drug supply under a license agreement with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun"). No revenue was recognized in the comparable prior year periods.
• Operating Expenses: Total operating expenses increased by $7.1 million in Q2 2026 compared to Q2 2025, driven primarily by a $7.3 million increase in Research and Development (R&D) expenses. R&D costs rose due to increased external costs for CROs/CMOs and personnel-related expenses to support clinical trials for CR-001 and CR-002.
• Other Income: The company recorded $1.8 million in other income for both Q2 and YTD 2026, resulting from the sale of legacy GlycoMimetics intellectual property assets. This was a non-recurring item not present in the prior year.
• Interest Expense: Interest expense was $0 for the current periods, compared to $1.1 million in Q2 2025. This reduction is due to the conversion of $37.5 million in convertible notes into equity during the reverse recapitalization in June 2025.
• Liquidity: Cash and cash equivalents decreased by approximately $41.6 million during the first six months of 2026, primarily due to operating losses and investing activities, including an $8.0 million withholding tax payment related to the Kelun agreement.

Guidance, Outlook, and Risks

• Clinical Progress: The company initiated the global Phase 1/2 "ASCEND" trial for CR-001 in Q1 2026. Initial safety and pharmacokinetic data are anticipated in Q1 2027. A Phase 1/2 trial for CR-002 is expected to initiate in the second half of 2026.
• Liquidity Outlook: Management expects existing cash ($171.6 million as of June 30, 2026) combined with proceeds from a July 2026 underwritten offering (net proceeds of approximately $133.5 million) to fund operations for at least twelve months from the filing date.
• Recent Financing: In July 2026, the company completed an underwritten public offering raising approximately $133.5 million and entered into an "at-the-market" (ATM) sales agreement allowing for the sale of up to $200.0 million of ordinary shares.
• Key Risks:
  • Capital Requirements: The company has never been profitable and expects to incur significant losses for the foreseeable future. Continued access to capital markets is critical.
  • Regulatory and Clinical Uncertainty: Success depends on the successful completion of clinical trials and regulatory approval, which are costly and uncertain.
  • Intellectual Property: The company does not own issued patents; its portfolio is in-licensed from Paragon Therapeutics and Kelun. Loss of these licenses would be material.
  • Third-Party Reliance: The company relies on third parties for manufacturing (including WuXi Biologics) and clinical trials. Geopolitical tensions and the U.S. BIOSECURE Act pose risks to supply chains involving Chinese entities.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $171.6 million cash balance plus the $133.5 million July 2026 proceeds against the projected burn rate, given the significant increase in R&D spending.
• Kelun Agreement Terms: Review the specific milestones and royalty obligations under the CR-001 license with Kelun, including the $5.0 million contingent consideration payable if a combination study is initiated.
• CR-001 Trial Data: Monitor the upcoming Q1 2027 data readout for the ASCEND trial, which is critical for validating the CR-001 program and future funding.
• IP Ownership: Confirm the status of in-licensed patents from Paragon and Kelun and any potential risks related to the termination of the ADC Paragon Option Agreement regarding Former CR-003.
• Supply Chain Risks: Assess the impact of the BIOSECURE Act and U.S.-China trade tensions on the company's reliance on WuXi Biologics and Kelun for manufacturing and development.